First-in-Human study of JNJ-55920839 in healthy volunteers and patients with systemic lupus erythematosus: a randomised placebo-controlled phase 1 trial
Activation of the type I interferon (IFN) pathway is associated with systemic lupus erythematosus (SLE) We assessed the safety and tolerability of JNJ-55920839, a human monoclonal antibody. The most common treatment-emergent adverse events were in the system organ class of infections and infestations. No other clinically significant safety or tolerability issues were identified.
